Alopecia

AbbVie submitted an sNDA to the FDA seeking approval of upadacitinib for severe alopecia areata in adults and adolescents.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

Check out exclusive expert interviews of late breaking data from AAD 2026.

In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).

Investigators observed disparities in race with persistent chemotherapy-induced alopecia among women with breast cancer.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

This systematic review and network meta-analysis was conducted to establish a hierarchy among approved oral JAK inhibitors for severe alopecia areata in adults.

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.